Ascentage Pharma Group International
NASDAQ:AAPGBiotechnology
+$0.31 today
- Market cap
- $1.16B
- Beta
- 0.65
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$13.29
Volume 0.00M
Average 0.01M
Balance Sheet
Inspect the capital base behind the business.
Assets
$3.97B
FY 2025 · Annual
+51.5% YoYLiabilities
$2.63B
FY 2025 · Annual
+12.3% YoYEquity
$1.34B
FY 2025 · Annual
+387.0% YoYBalance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.71B | 1.48B | 1.07B | 1.24B | 2.47B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 54.13M | 61.49M | 163.54M | 99.07M | 253.1M |
| Inventory | 3.93M | 9.45M | 16.17M | 6.6M | 28.64M |
| Other Current Assets | 59.26M | 16.6M | 24.54M | 24.63M | 192.65M |
| Total Current Assets | 1.89B | 1.64B | 1.34B | 1.47B | 2.95B |
| Property, Plant & Equipment (Net) | 854.3M | 650.03M | 957.23M | 905.86M | 829.59M |
| Goodwill | 24.69M | 24.69M | 24.69M | 24.69M | 24.71M |
| Intangible Assets | 60.41M | 84.3M | 85.45M | 76M | 65.98M |
| Long-term Investments | 27.85M | 18.53M | 18.95M | 33.86M | 37.05M |
| Tax Assets | 51.65M | 54.29M | 59.84M | 44.24M | 31.98M |
| Other Non-current Assets | 35.88M | 361.93M | 10.05M | 59M | 30.74M |
| Total Non-current Assets | 1.05B | 1.19B | 1.16B | 1.14B | 1.02B |
| Total Assets | 2.94B | 2.83B | 2.5B | 2.62B | 3.97B |
| Account Payables | 70.86M | 95.56M | 72.45M | 91.97M | 106.81M |
| Short-term Debt | 39.8M | 510.31M | 606.65M | 769.62M | 1.22B |
| Tax Payables | 3.28M | 7.18M | 8.39M | 9.63M | 0 |
| Deferred Revenue | 0 | 24.35M | 38.41M | 54.09M | 37.51M |
| Other Current Liabilities | 58.73M | 2.82M | 0 | 0 | 276.84M |
| Total Current Liabilities | 361.11M | 881.15M | 934.17M | 1.17B | 1.64B |
| Long-term Debt | 1.03B | 1.27B | 1.17B | 868.64M | 742.8M |
| Deferred Tax Liabilities | 13.75M | 12.15M | 10.55M | 5.37M | 0 |
| Deferred Revenue (Non-current) | 243.28M | 218.63M | 287.55M | 275.96M | 216.86M |
| Other Non-current Liabilities | 52.34M | 35.33M | 18.3M | 6.27M | 12.04M |
| Total Non-current Liabilities | 1.34B | 1.54B | 1.5B | 1.18B | 986.62M |
| Total Liabilities | 1.71B | 2.42B | 2.43B | 2.34B | 2.63B |
| Common Stock | 178K | 180K | 197K | 214K | 256.16K |
| Retained Earnings | (3.56B) | (4.44B) | (5.37B) | (5.77B) | 0 |
| Accumulated OCI | (550.95M) | (518.51M) | (504.46M) | (510.59M) | 1.33B |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 10.22M | 9.97M | 9.76M |
| Total Equity | 1.23B | 408.66M | 70.63M | 274.16M | 1.34B |
| Total Debt | 1.08B | 1.79B | 1.8B | 1.67B | 1.98B |
| Net Debt | (622.6M) | 317.09M | 726.3M | 431.92M | (490.68M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $2.5B |
| Receivables | $253.1M |
| Inventory | $28.6M |
| Other Current | $192.7M |
| Total Current Assets | $2.9B |
| PP&E (Net) | $829.6M |
| Goodwill | $24.7M |
| Intangible Assets | $66.0M |
| Long-term Investments | $37.1M |
| Tax Assets | $32.0M |
| Other Non-current | $30.7M |
| Total Non-current Assets | $1.0B |
| Total Assets | $4.0B |
Analysis
Selected assets total $4.0B for Latest. The largest visible component is Cash & Equivalents at $2.5B, about 62.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 5, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| 6-K | 6-K filing | Oct 21, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 |
How much cash does AAPG have?
Ascentage Pharma Group International (AAPG) reported $2.47B in cash and equivalents in fiscal 2025.
How much debt does AAPG carry?
Ascentage Pharma Group International (AAPG) reported $1.98B of total debt, with net debt of -$490.68M.
Continue the stock analysis
Jump to another research area for this company.